Table 1 Demographic and clinical characteristics of the enrolled patients
| Â | SLE patients | Control group | ||
|---|---|---|---|---|
Number of patients | 74 | 34 | ||
Age mean (min–max) | 40 (19–74) | 40 (24–50) | ||
Female/Male | 65/9 | 29/5 | ||
|  | SLE (n = 74) | |||
Duration of disease (years) mean (min–max) | 11.3 (1–38) | |||
Nonsmokers/Stop smoking/Smokers (percentage) | 64.9/16.2/18.9 | |||
SLEDAI-2 K mean (min–max) | 7.0 (0–43) | |||
SLICC/ACR DI mean (min–max) | 1.21 (0‒8) | |||
C3 level (g/l) mean (min–max) | 0.88 (0.2‒1.72) | |||
C4 level (g/l) mean (min–max) | 0.14 (0.06‒0.3) | |||
| Â | SLE cohort | Active LN-SLE group | Inactive LN-SLE group | No LN-SLE group |
Number of patients | 74 | 11 | 14 | 47 |
Anti ds DNA IgG positive | 46 (62.2%) | 6 (54.5%) | 12 (85.7%) | 28 (59.6%) |
Anti ds DNA IgG (IU/ml) mean when positive (min–max) | 80.47 (21‒ >200) | 141.3 (24‒200) | 96.4 (26‒200) | 91.1 (21‒200) |
Anti-Smith antibody positive | 16 (21.6%) | 3 (27.3%) | 3 (21.4%) | 8 (17%) |
Anti-nucleosome antibodies positive | 61 (82.4%) | 10 (100%) | 12 (85.7%) | 37 (78.7%) |
Anti-nucleosome antibodies mean when positive (IU/ml) (min–max) | 105.37 (1.7‒ >200) | 145.3 (32‒ >200) | 145.5 (46‒ >200) | 122.5 (27‒ >200) |
Active LN– Proteinuria (mean - g/day) |  | 1.5 (0.36‒6.03) |  |  |
Proteinuria (> 0.5 g/day)/Hematuria/Pyuria (number of patients) |  | 11/4/7 |  |  |